Homologous veins as an arterial substitute: long-term results.
From 1968 through 1982, 129 homologous vein grafts were used in 91 patients in the following positions: 75 in the femoropopliteal, tibial, or peroneal artery; 38 in the aortocoronary artery; 13 in the aortopulmonary artery; and one each in the atrioventricular fistula, carotid-subclavian artery, and brachial-radial artery. In the lower extremity patency ranged from 0 to 121 months (mean 22.4 +/- 4.4 months). All grafts were performed for limb salvage, and 75% of the patients had undergone previous operations. Cumulative patency by the life-table method showed that while 50% of grafts occluded by 1 year, 60% of the remaining grafts continued to be functional for more than 5 years. Fifty percent of the aortocoronary bypass grafts studied were occluded at 1 year. Eight of the 13 systemic pulmonary artery shunts were patent at time of death, revision, or total correction. Multiple revisions and thrombectomies are required to maintain patency of homograft veins. The outcome is variable and unpredictable. The inconsistency is due to the antigenicity of the graft. If one is committed to the necessary efforts required to ensure long-term patency, the homologous saphenous vein is a suitable substitute when autogenous tissue is unavailable.
D001157:Arterial Occlusive Diseases / Q000628:therapy; D001166:Arteriovenous Shunt, Surgical; D001807:Blood Vessel Prosthesis; D001916:Brachial Artery / Q000601:surgery; D003327:Coronary Disease / Q000628:therapy; D006330:Heart Defects, Congenital / Q000628:therapy; D006801:Humans; D007866:Leg / Q000098:blood supply; D012501:Saphenous Vein / Q000637:transplantation*; D014184:Transplantation, Homologous